Free tool
FAERS Monitor: Opdivo Qvantig
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761381 or its brand name (Opdivo Qvantig, Nivolumab, Hyaluronidase-Nvhy). Reports on generic versions are filed under their own applications.
Reports
136
Serious
36
26% of reports
Hospitalization
8
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use35
- fatigue12
- rash12
- product storage error11
- arthralgia10
- death8
- diarrhoea7
- constipation6
- decreased appetite6
- product dose omission issue6
- nausea5
- product storage issue5
- dizziness4
- malignant neoplasm progression4
- myalgia4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 43 |
| 2026 | 93 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,023 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product storage issueSignal | 5 | 204.4 | 86.4 | 818 |
| product storage errorSignal | 11 | 19.4 | 11.0 | 175 |
| off label useSignal | 35 | 6.2 | 4.6 | 153 |
| malignant neoplasm progressionSignal | 4 | 6.0 | 2.3 | 12 |
| rashSignal | 12 | 4.3 | 2.5 | 27 |
| constipationSignal | 6 | 4.3 | 1.9 | 12 |
| decreased appetiteSignal | 6 | 4.0 | 1.8 | 11 |
| arthralgiaSignal | 10 | 3.7 | 2.0 | 18 |
| myalgiaSignal | 4 | 3.6 | 1.4 | 5 |
| product dose omission issueSignal | 6 | 3.2 | 1.4 | 7 |
| fatigueSignal | 12 | 2.4 | 1.4 | 9 |
| diarrhoea | 7 | 1.7 | 0.8 | 1 |
| death | 8 | 1.4 | 0.7 | 1 |
| dizziness | 4 | 1.2 | 0.5 | 0 |
| nausea | 5 | 1.0 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.